Bellicum Announces Data Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant in Children with Blood Cancers & Nonmalignant Diseases

December 9, 2017 by Website Admin in

Bellicum announced results from a leading European transplant center participating in the BP-004 trial in children with blood cancers and nonmalignant disorders.

Tweet

Share

Pin it

Previous StoryLivaNova to Acquire ImThera Medical, Inc. Next StoryBellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting